AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17951035 — intervention group
Group type: EXPERIMENTAL
Intervention: HHQ-free coffee (middle-dose)
Number of subjects: 203
Study 17951035 — intervention group
Group type: EXPERIMENTAL
Intervention: HHQ-free coffee (high-dose)
Number of subjects: 203
Study 17951035 — intervention group
Group type: COMPARATOR
Intervention: Ordinary coffee (control)
Number of subjects: 203
Study 16750285 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar vaccination (controlled inhalation of Pneumovax)
Number of subjects: 0
Study 16750285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial vaccination (controlled inhalation of Pneumovax)
Number of subjects: 0
Study 16750285 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular vaccination (control group)
Number of subjects: 0
Study 12860336 — intervention group
Group type: EXPERIMENTAL
Intervention: rec‐FSH
Number of subjects: 31
Study 12860336 — intervention group
Group type: COMPARATOR
Intervention: urinary FSH (u‐FSH)+hMG
Number of subjects: 31
Study 12860336 — intervention group
Group type: COMPARATOR
Intervention: u‐FSH only
Number of subjects: 31
Study 15077096 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 249
Study 15077096 — intervention group
Group type: COMPARATOR
Intervention: Stenting after predilatation
Number of subjects: 249
Study 10661784 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating gait orthosis (RGO)
Number of subjects: 22
Study 10661784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip guidance orthosis (HGO)
Number of subjects: 22
Study 10661784 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HGO and RGO
Number of subjects: 22
Study 7747686 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide, 500 micrograms/24 hours subcutaneously
Number of subjects: 10
Study 7747686 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal subjects matched for sex and age)
Number of subjects: 10
Study 2127537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone with low-dose flecainide
Number of subjects: 0
Study 2127537 — intervention group
Group type: COMPARATOR
Intervention: Flecainide and encainide
Number of subjects: 0
Study 7248985 — intervention group
Group type: EXPERIMENTAL
Intervention: iv vincristine, intrathecal methotrexate, and intrathecal hydrocortisone
Number of subjects: 0
Study 7248985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28330831 — intervention group
Group type: EXPERIMENTAL
Intervention: iMIND (n=604)
Number of subjects: 1255
Study 28330831 — intervention group
Group type: COMPARATOR
Intervention: iCBT (n=651)
Number of subjects: 1255
Study 25609761 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated short-answer quizzing
Number of subjects: 35
Study 25609761 — intervention group
Group type: COMPARATOR
Intervention: Repeated studying
Number of subjects: 35
Study 25609761 — intervention group
Group type: COMPARATOR
Intervention: No further exposure
Number of subjects: 35
Study 24195862 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative Tai Chi Rehabilitation Program (ITCRP) - tai chi two or three times a week for 6 months
Number of subjects: 140
Study 24195862 — intervention group
Group type: COMPARATOR
Intervention: Control group - health education
Number of subjects: 140
Study 21341932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track diagnosis and treatment program for CRC
Number of subjects: 156
Study 21341932 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual pathways)
Number of subjects: 156
Study 21341932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pathways (fast track and control)
Number of subjects: 156
Study 19808342 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 8290
Study 19808342 — intervention group
Group type: COMPARATOR
Intervention: Control (no trandolapril)
Number of subjects: 8290
Study 17996561 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (titrated to a target of 32 mg once daily)
Number of subjects: 7599
Study 17996561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study 15037057 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional narratives in AD patients
Number of subjects: 80
Study 15037057 — intervention group
Group type: COMPARATOR
Intervention: Emotional narratives in control participants
Number of subjects: 80
Study 11417441 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 7
Study 11417441 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet
Number of subjects: 7
Study 9603181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 11
Study 9603181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7826795 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiled-tipped catheter
Number of subjects: 0
Study 7826795 — intervention group
Group type: COMPARATOR
Intervention: Standard straight-tipped catheter
Number of subjects: 0
Study 7826795 — intervention group
Group type: COMPARATOR
Intervention: 32-gauge microcatheter (TFX)
Number of subjects: 0
Study 2843066 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg morphine sulfate intrathecally
Number of subjects: 20
Study 2843066 — intervention group
Group type: COMPARATOR
Intervention: 0.75 mg morphine sulfate intramuscularly (control)
Number of subjects: 20
Study 31512072 — intervention group
Group type: EXPERIMENTAL
Intervention: UV irradiated surface-treated implants
Number of subjects: 180
Study 31512072 — intervention group
Group type: COMPARATOR
Intervention: Original surface implants (control)
Number of subjects: 180
Study 31346895 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic dressing group (3M® Tegaderm® CHG)
Number of subjects: 104
Study 31346895 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard drain care)
Number of subjects: 104
Study 28921814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 2 mg/day for 10 weeks
Number of subjects: 18
Study 28921814 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 18
Study 25528200 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 2.5 mg
Number of subjects: 117
Study 25528200 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 5 mg
Number of subjects: 117
Study 25528200 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 20 mg
Number of subjects: 117
Study 25528200 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (all doses)
Number of subjects: 117
Study 25528200 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 117
Study 24088722 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (4 h/night)
Number of subjects: 10
Study 24088722 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (8 h/night)
Number of subjects: 10
Study 21196829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 0
Study 21196829 — intervention group
Group type: COMPARATOR
Intervention: Articaine 4% with epinephrine 1:200 000
Number of subjects: 0
Study 19296355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized controlled trials
Number of subjects: 0
Study 19296355 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially effective treatments
Number of subjects: 0
Study 17464603 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block (group F)
Number of subjects: 80
Study 17464603 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri‐ and intraarticular infiltration with 300 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine (group I)
Number of subjects: 80
Study 15111692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated, normalized technique with full brain coverage (SIENA)
Number of subjects: 0
Study 15111692 — intervention group
Group type: COMPARATOR
Intervention: Semiautomated, nonnormalized technique with partial brain coverage
Number of subjects: 0
Study 12297933 — intervention group
Group type: EXPERIMENTAL
Intervention: Incised mesh
Number of subjects: 360
Study 12297933 — intervention group
Group type: COMPARATOR
Intervention: Non-incised mesh
Number of subjects: 360
Study 12297933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip fixation
Number of subjects: 360
Study 12297933 — intervention group
Group type: COMPARATOR
Intervention: Suturing the mesh
Number of subjects: 360
Study 12297933 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of Nyhus type II hernias
Number of subjects: 360
Study 12297933 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex flow examination of testicular vessels
Number of subjects: 360
Study 9797056 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpick method
Number of subjects: 20
Study 9797056 — intervention group
Group type: COMPARATOR
Intervention: Bass method
Number of subjects: 20
Study 7611638 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 23
Study 7611638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2236584 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable, head-mounted phototherapy device
Number of subjects: 0
Study 2236584 — intervention group
Group type: COMPARATOR
Intervention: Standard light box
Number of subjects: 0
Study 340005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (nicoumalone) treatment
Number of subjects: 145
Study 340005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin calcium
Number of subjects: 145
Study 340005 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous saline
Number of subjects: 145
Study 30942036 — intervention group
Group type: EXPERIMENTAL
Intervention: Lieque (LU 7) acupuncture
Number of subjects: 36
Study 30942036 — intervention group
Group type: COMPARATOR
Intervention: Jingqu (LU 8) acupuncture
Number of subjects: 36
Study 26832859 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI) - 32 Gy in eight fractions over 5-6 days
Number of subjects: 183
Study 26832859 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) - 50 Gy in fractions of 2 Gy for 5 weeks
Number of subjects: 183
Study 26832859 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 183
Study 26832859 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 183
Study 25353078 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration exercise warm-up (VbX)
Number of subjects: 3
Study 25353078 — intervention group
Group type: EXPERIMENTAL
Intervention: Deadlift-specific warm-up (DL-WU)
Number of subjects: 3
Study 25353078 — intervention group
Group type: COMPARATOR
Intervention: Control (body-weight squats without vibration)
Number of subjects: 3
Study 21349113 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg at weeks 0, 2, and 6
Number of subjects: 24
Study 21349113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21349113 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 24
Study 19557959 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 60
Study 19557959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask (ILMA)
Number of subjects: 60
Study 16675939 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 mg kg(‐1) h(‐1)
Number of subjects: 40
Study 16675939 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2‐3 mg kg(‐1) h(‐1)
Number of subjects: 40
Study 15251635 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion for at least 24 hours followed by long-term subcutaneous insulin treatment
Number of subjects: 0
Study 15251635 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment in patients without prior insulin treatment
Number of subjects: 0
Study 15251635 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11744471 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for 3 months)
Number of subjects: 60
Study 11744471 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 60
Study 11744471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9285267 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrams of neutral, food, and threat words (Study 1)
Number of subjects: 80
Study 9285267 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrams of words reflecting physical threat, self-directed ego threat, and ego threat directed from others (Study 2)
Number of subjects: 80
Study 8440854 — intervention group
Group type: EXPERIMENTAL
Intervention: Various intervention strategies tested at eight FICSIT sites
Number of subjects: 0
Study 8440854 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared descriptive (risk-adjustment) measures and outcome measures
Number of subjects: 0
Study 3325220 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 20
Study 3325220 — intervention group
Group type: COMPARATOR
Intervention: Multiple insulin injections (MII) using a pen injector
Number of subjects: 20
Study 3325220 — intervention group
Group type: COMPARATOR
Intervention: Multiple insulin injections (MII)
Number of subjects: 20
Study 31366262 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (once-daily DPP-4i)
Number of subjects: 60
Study 31366262 — intervention group
Group type: COMPARATOR
Intervention: Trelagliptin (once-weekly DPP-4i)
Number of subjects: 60
Study 31366262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Alogliptin and Trelagliptin)
Number of subjects: 60
Study 29894598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 63
Study 29894598 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI) treatment
Number of subjects: 63
Study 29894598 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 63
Study 27510533 — intervention group
Group type: COMPARATOR
Intervention: Nonalkalized cocoa mixture containing 0.6 mg epicatechin, 0.2 mg catechin, and 2.9 mg monomer-decamer procyanidins/kg body weight
Number of subjects: 28
Study 27510533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of epicatechin and nonalkalized cocoa mixture containing 1.6 mg epicatechin/kg body weight
Number of subjects: 28
Study 24476418 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin with concomitant azithromycin
Number of subjects: 263
Study 24476418 — intervention group
Group type: COMPARATOR
Intervention: Inhaled aztreonam lysine
Number of subjects: 263
Study 24476418 — intervention group
Group type: COMPARATOR
Intervention: Inhaled tobramycin without azithromycin
Number of subjects: 263
Study 24476418 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro testing of P. aeruginosa isolates
Number of subjects: 263
Study 22626813 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel prewarmed to 37 °C
Number of subjects: 180
Study 22626813 — intervention group
Group type: COMPARATOR
Intervention: I-gel kept at room temperature (approximately 20 °C)
Number of subjects: 180
Study 20724949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation (0.1, 0.2, and 0.4 g/kg)
Number of subjects: 22
Study 20724949 — intervention group
Group type: COMPARATOR
Intervention: Control group (Healthy Controls)
Number of subjects: 22
Study 20724949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation
Number of subjects: 22
Study 18597900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza vaccine (LAIV)
Number of subjects: 243
Study 18597900 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular trivalent inactivated influenza vaccine (TIV)
Number of subjects: 243
Study 15116063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 30
Study 15116063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11487753 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron formula (20.7 mg iron/L)
Number of subjects: 58
Study 11487753 — intervention group
Group type: COMPARATOR
Intervention: Normal iron formula (13.4 mg iron/L)
Number of subjects: 58
Study 9724157 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefotiam
Number of subjects: 84
Study 9724157 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 84
Study 8279610 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored mammography recommendation letters
Number of subjects: 435
Study 8279610 — intervention group
Group type: COMPARATOR
Intervention: Standardized mammography recommendation letters
Number of subjects: 435
Study 2918287 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial urine assays for detection of cocaine use
Number of subjects: 0
Study 2918287 — intervention group
Group type: COMPARATOR
Intervention: KDI Quik Test
Number of subjects: 0
Study 2918287 — intervention group
Group type: COMPARATOR
Intervention: Gas chromatography/mass spectrometry (GC/MS)
Number of subjects: 0
Study 801345 — intervention group
Group type: EXPERIMENTAL
Intervention: Beconase (beclomethasone diproprionate)
Number of subjects: 32
Study 31296251 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (50 mg/kg) and thiamine (200 mg) administered intravenously every 12 hours for 48 hours
Number of subjects: 116
Study 31296251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) administered in identical volume and manner as the treatment group
Number of subjects: 116
Study 28596642 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg daily for 3 months
Number of subjects: 12
Study 28596642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24633992 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (LKM)
Number of subjects: 38
Study 24633992 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 38
Study 22832536 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow movement and tonic force generation (LST; 3-s eccentric, 3-s concentric, and 1-s isometric actions with no rest between repetitions)
Number of subjects: 35
Study 22832536 — intervention group
Group type: COMPARATOR
Intervention: Normal speed (LN; 1-s concentric and 1-s eccentric actions with 1-s rests between repetitions)
Number of subjects: 35
Study 21939502 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking group
Number of subjects: 3994
Study 21939502 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3994
Study 19108791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg plus lisinopril 5 mg
Number of subjects: 47
Study 19108791 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 25 mg
Number of subjects: 47
Study 19108791 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 5 mg
Number of subjects: 47
Study 16813787 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 19
Study 16813787 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 19
Study 16258445 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0
Study 16258445 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation
Number of subjects: 0
Study 16258445 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and radiation
Number of subjects: 0
Study 16258445 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative therapy
Number of subjects: 0
Study 16258445 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomized trials
Number of subjects: 0
Study 11780728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking task at three different levels of task difficulty
Number of subjects: 12
Study 9418187 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed streptococcal preparation (KSP), low doses administered before and during early pregnancy.
Number of subjects: 228
Study 9418187 — intervention group
Group type: COMPARATOR
Intervention: Paternal lymphocyte immunotherapy (control group).
Number of subjects: 228
Study 9418187 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cell activity assessment.
Number of subjects: 228
Study 8270363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus cefotaxime or aminoglycoside (N=17)
Number of subjects: 62
Study 8270363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus aminoglycoside (N=59)
Number of subjects: 62
Study 8270363 — intervention group
Group type: COMPARATOR
Intervention: Healthy newborns (N=45)
Number of subjects: 62
Study 3094846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 122
Study 3094846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 3094846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (high blood level)
Number of subjects: 122
Study 31811383 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (endoscope introduced between the septum and inferior turbinate)
Number of subjects: 60
Study 31811383 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (endoscope introduced between the inferior turbinate and middle turbinate)
Number of subjects: 60
Study 31811383 — intervention group
Group type: COMPARATOR
Intervention: Group 1 and Group 2
Number of subjects: 60
Study 30502982 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-AIT (ab interno trabeculectomy with Trabectome combined with cataract surgery)
Number of subjects: 19
Study 30502982 — intervention group
Group type: COMPARATOR
Intervention: Phaco-Trab (Trabeculectomy with mitomycin C combined with cataract surgery)
Number of subjects: 19
Study 26428322 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of an external ventricular drain
Number of subjects: 413
Study 26428322 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing volume of cerebrospinal fluid (CSF) drainage per day
Number of subjects: 413
Study 26428322 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily CSF output threshold of 78 mL
Number of subjects: 413
Study 26428322 — intervention group
Group type: COMPARATOR
Intervention: Overall VPS insertion rate among 41,789 patients with aSAH from 66 studies
Number of subjects: 413